Cargando…
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
Autores principales: | Jaeger, Ulrich, Tam, Constantine S., Borchmann, Peter, McGuirk, Joseph P., Johansen, Marianne, Waller, Edmund K., Jaglowski, Samantha, Andreadis, Charalambos, Foley, Stephen R., Westin, Jason R., Fleury, Isabelle, Ho, P. Joy, Mielke, Stephan, Teshima, Takanori, Salles, Gilles, Schuster, Stephen J., He, Fiona, Maziarz, Richard T., Mayer, Sebastian, Makita, Shinichi, Kersten, Marie J., Ghosh, Monalisa, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Goto, Hideki, Colicino, Silvia, Agarwal, Abhijit, Lobetti-Bodoni, Chiara, Bishop, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631665/ https://www.ncbi.nlm.nih.gov/pubmed/35687492 http://dx.doi.org/10.1182/bloodadvances.2021006193 |
Ejemplares similares
-
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
por: Jaeger, Ulrich, et al.
Publicado: (2022) -
P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022) -
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
por: Salles, Gilles, et al.
Publicado: (2022) -
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021) -
Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)